April 22nd 2025
In comparison to native 64-mT MRI, the deep learning generative model LowGAN offered enhanced white matter lesion conspicuity and image quality in a study involving patients with multiple sclerosis.
Meta-Analysis of 83 MRI Studies Suggests Link Between Adversity Exposure and Mental Health Issues
November 3rd 2023In their review of functional MRI data from over 5,200 study participants, researchers noted that higher amygdala reactivity and lower prefrontal cortical reactivity were associated with adversity exposure, findings that may contribute to exaggerated threat detection and reduced emotional control.
Current and Emerging Perspectives on Contrast Media in Radiology
November 1st 2023In a recent video interview series, Dushyant Sahani, M.D., discussed the critical role of contrast media in diagnostic imaging, lessons learned from the contrast media shortage, key considerations with generic agents and currently unmet needs with contrast agents.
FDA Clears AI-Enabled Denoising Feature for DWI Sequences on Portable Brain MRI System
October 9th 2023In reportedly the eighth FDA 510(k) clearance for Hyperfine’s Swoop portable brain MRI device, clinicians will now have access to enhanced denoising capabilities with diffusion-weighted imaging (DWI) sequences.
MRI Study: Half-Dose Gadopiclenol Offers Similar Visualization and Safety as Full-Dose Gadobutrol
July 20th 2023Newly published research suggests the use of gadopiclenol at 0.05 mmol/kg is non-inferior to gadobutrol 0.1 mmol/kg for all qualitative visualization parameters on full-body magnetic resonance imaging (MRI).
Can AI Bolster MRI Lesion Detection and Segmentation in Patients with Multiple Sclerosis?
July 19th 2023An artificial intelligence model, trained on MRI and FLAIR imaging from over 900 patients with multiple sclerosis, demonstrated a 96 percent accuracy rate and 99 percent specificity rate for contrast-enhancing lesions in this patient population.
Icometrix Gets First CPT III Code Issued by AMA for AI Brain MRI Software
July 3rd 2023Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.